Want to see FR:ALTME full AI Analyst Report?
ALTME Stock Chart & Stats
€0.13
<€0.01(1.94%)
At close: 4:00 PM EDT
€0.13
<€0.01(1.94%)
Day’s Range― - ―
52-Week Range€0.05 - €0.17
Previous CloseN/A
Volume71.91K
Average Volume (3M)4.70M
Market Cap
€10.82M
Enterprise Value€7.83M
Total Cash (Recent Filing)€2.02M
Total Debt (Recent Filing)€2.39M
Price to Earnings (P/E)―
Beta-0.55
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding94,988,980
10 Day Avg. Volume3,165,711
30 Day Avg. Volume4,704,527
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.89
Price to Sales (P/S)0.00
P/FCF Ratio-1.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.15
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
CNS Oncology FocusA focused CNS oncology strategy can help concentrate research resources and expertise around a defined area of high unmet need. Specialization may support differentiated scientific positioning and create a clearer basis for future clinical development or partnering opportunities.
Clinical Development PipelineAn active development pipeline provides the company with potential clinical and commercial catalysts beyond its current financial profile. Progressing candidates through preclinical and clinical stages can build asset value and preserve multiple routes toward future commercialization.
Partnering OptionalityThe stated potential for commercialization or partnering gives TME Pharma more than one route to realize value from its research assets. A credible partnering pathway could provide development support, external expertise, or future funding if candidates demonstrate sufficient promise.
Bears Say
Minimal Revenue And Persistent LossesThe company has not yet established a meaningful revenue base and remains far from breakeven. Persistent operating losses reduce financial resilience and make future progress dependent on successful development, commercialization, or additional funding over the coming quarters.
Negative Equity And Rising DebtNegative equity and sharply higher debt indicate a pressured capital structure and reduced financial flexibility. This raises solvency and financing risk, while any need to strengthen the balance sheet could constrain operations or increase dependence on external capital.
Persistent Cash BurnRecurring negative operating and free cash flow shows that the business currently consumes cash rather than funding itself. The renewed deterioration in 2025 reinforces reliance on external funding, potentially limiting the pace and durability of ongoing development activities.
TME Pharma N.V. News
ALTME FAQ
What was TME Pharma N.V.’s price range in the past 12 months?
TME Pharma N.V. lowest stock price was €0.05 and its highest was €0.17 in the past 12 months.
What is TME Pharma N.V.’s market cap?
TME Pharma N.V.’s market cap is €10.82M.
When is TME Pharma N.V.’s upcoming earnings report date?
TME Pharma N.V.’s upcoming earnings report date is Oct 29, 2026 which is in 38 days.
How were TME Pharma N.V.’s earnings last quarter?
TME Pharma N.V. released its earnings results on Oct 30, 2025. The company reported -€0.022 earnings per share for the quarter.
Is TME Pharma N.V. overvalued?
According to Wall Street analysts TME Pharma N.V.’s price is currently Overvalued.
Does TME Pharma N.V. pay dividends?
TME Pharma N.V. does not currently pay dividends.
What is TME Pharma N.V.’s EPS estimate?
TME Pharma N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TME Pharma N.V. have?
TME Pharma N.V. has 94,988,980 shares outstanding.
What happened to TME Pharma N.V.’s price movement after its last earnings report?
TME Pharma N.V. reported an EPS of -€0.022 in its last earnings report. Following the earnings report the stock price went up 5.479%.
Which hedge fund is a major shareholder of TME Pharma N.V.?
Currently, no hedge funds are holding shares in FR:ALTME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TME Pharma N.V.
TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipeline of investigational drug candidates. Its primary oncology asset, NOX-A12, is currently being evaluated in clinical studies as a combination therapy for a range of challenging cancers, including metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. Beyond its cancer-focused efforts, TME Pharma also developed NOX-E36, which has successfully concluded Phase 1/2 clinical trials for diabetic nephropathy. The company has formed a strategic collaboration with Merck Sharp & Dohme Corp. to explore NOX-A12 in combination with Keytruda and two different chemotherapy protocols as a second-line intervention for patients battling metastatic pancreatic cancer. Founded in 1997, the organization adopted its current name, TME Pharma N.V., in July 2022, having previously operated as NOXXON Pharma N.V.
Technical Analysis
Innate Pharma SA
―
Nanobiotix
―
Transgene
―
OSE Immunotherapeutics SA
―
Cellectis SA
―